VT-111 has the potential to be one of the first true anti-inflammatory drugs to market to treat cardiovascular inflammation and transplant vasculopathy.

VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition ^(1,2).  VT-111 is an extremely potent inhibitor of vascular inflammation and is being used at doses much lower than most biologics on the market today (µg/kg). VT-111 dramatically reduces leukocyte recruitment to sites of inflammation at low doses in vivo and has demonstrated efficacy in over 40 animal models of disease including angioplasty, stent placement, cardiovascular bypass surgery and solid organ (heart and kidney) transplantation.

VT-111 has demonstrated a favorable safety profile (safe, well tolerated in Phase I), and is currently enrolling ACS patients in a Phase IIa study with primary endpoints designed to establish safety in patients undergoing purcutaneous coronary interventions (PCI), and gather information on the drug's effects on biomarkers and intravascular ultrasound at a six month follow-up.

VT-111 is currently undergoing manufacturing scale up for late stage clinical trials and market launch, and is preparing to file an IND in solid organ transplant, its second indication.